Last reviewed 2026-04-20 · How we verify

Rivfloza (NEDOSIRAN)

Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production.

At a glance

Mechanism of action

Nedosiran is a siRNA that targets the liver. It binds to specific receptors on liver cells, which allows it to enter and degrade the mRNA for LDHA, a protein involved in producing oxalate. By reducing LDHA, it lowers oxalate levels.

Approved indications

• primary hyperoxaluria type 1
• primary hyperoxaluria type 1

Common side effects

• Injection site reactions
• Erythema
• Pain
• Bruising
• Rash
• Atrophy

Key clinical trials

• Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD (PHASE2)
• Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function (PHASE2)
• Treatment of Primary Hyperoxaluria Type 1 With Nedosiran
• Long Term Extension Study in Patients With Primary Hyperoxaluria (PHASE3)
• Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients (PHASE1)
• A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Rivfloza CI brief — competitive landscape report
• Rivfloza updates RSS · CI watch RSS
• Novo portfolio CI